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There is growing evidence for multifunctional properties of IL-32. We previously demonstrated that
IL-32b upregulates IL-10 production through the association with PKCd. In this study, we examined
the effects of other IL-32 isoforms on IL-10 production. We found that IL-32d decreased IL-10 pro-
duction and investigated the inhibitory mechanism of IL-32d. We showed that IL-32d suppressed
IL-32b binding to PKCd by interacting with IL-32b. The inhibitory effect of IL-32d on IL-32b associa-
tion with PKCd was further veriﬁed by immuno-ﬂuorescence staining. The co-localization of IL-32b
and PKCd around the nuclear membrane was disrupted by IL-32d. Our data therefore indicate that
IL-32d plays an inhibitory role against IL-32b function, which also suggests that IL-32 may be regu-
lated by its own isoform.
Structured summary of protein interactions:
PKC delta physically interacts with IL-32 beta by anti bait coimmunoprecipitation (View interaction)
IL-32 beta physically interacts with PKC delta by anti tag coimmunoprecipitation (View interaction)
IL-32 beta physically interacts with IL-32 delta by anti tag coimmunoprecipitation (1, 2)
PKC delta and IL-32 beta colocalize by ﬂuorescence microscopy (view interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Interleukin-32 (IL-32) was originally reported as a transcript
that induced in IL-2-activated natural killer (NK) cell or mitogen-
activated T cell [1]. A variety of cell types such as epithelial, endo-
thelial, NK cell, T cell, and dendritic cell express IL-32 [2–4] and the
expression of IL-32 is generally induced under inﬂammation or
infection with mycobacterium tuberculosis, Epstein–Barr virus,
HIV and Inﬂuenza A virus [5–8].
A sequence analysis revealed that IL-32 does not belong to any
established cytokine family and that various isoforms exist, but the
biological role of each isoform remains to be deﬁned [9]. Although
IL-32 has been shown to be secreted when overexpressed [10],
multiple studies have demonstrated the preponderance of IL-32
protein in cellular lysates rather than in the supernatant [4,11–
13]. Moreover, the cell surface receptor for IL-32 has not yet been
identiﬁed despite extensive investigation, which raises a questionregarding whether IL-32 functions intracellularly or extracellu-
larly. IL-32 has pleiotropic effects on cellular function such as the
induction of pro- or anti-inﬂammatory cytokine [14–16], cell apop-
tosis [4,17], and cell differentiation [18–20]. Moreover, IL-32 is ex-
pressed in various cell types. These evidences suggest the cell-type
speciﬁc expressions of IL-32 isoforms and their different roles in
different cells. Recently, IL-32a is reported to associate with PKCe
and STAT3 [21] or with integrins and focal adhesion kinase 1
(FAK1) [22]. IL-32b is also known to promote IL-10 production in
a PKCd-mediated way [23]. In this study, we investigated the effect
of IL-32d and demonstrated how it functions in cells.
2. Materials and methods
2.1. Reagents and cell culture
Human histocytic U937 leukemia cells were grown in RPMI
1640 (WelGENE, Daegu, Korea) supplemented with 2 mM L-gluta-
mine, 100 U/ml penicillin, 100 lg/ml streptomycin, and 10% fetal
bovine serum (Hyclone, Logan, UT). Human embryonic kidney
293 cells and human lung carcinoma A549 cells were maintained
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100 U/ml penicillin, 100 lg/ml streptomycin, and 10% fetal bovine
serum (Hyclone). Phorbol 12-myristate 13-acetate (PMA) was pur-
chased from Sigma (St. Louis, MO), and the PKCd inhibitor rottlerin
was purchased from Calbiochem (San Diego, CA).
2.2. Cloning of IL-32 isoforms
The cDNAs of IL-32 (a, b, and c) were kindly provided by Dr. SH
Kim (Seoul, Konkuk University). IL-32e cDNA was cloned from
THP-1 cells by RT-PCR. IL-32d and IL-32f cDNAs were prepared
by PCR using an IL-32d-speciﬁc or IL-32f-speciﬁc forward primer
and IL-32b as the template. The primers are; IL-32d sense:
50-GACGAATTCATGAAGAAGCTGAAG-30, IL-32f sense: 50-GGTGAA
TTCATGCAAAATGCAGAA-30, and common antisense: 50-GCGCTC
GAGTTTTGAGGATT GGGG-30. Each IL-32 isoform was excised by
EcoRI and XhoI, and then subcloned into pcDNA3.1+ 6myc vector.
IL-32b and IL-32d were also subcloned into pcDNA3.1+ 5ﬂag
vector.
2.3. Electroporation and ELISA
U937 promonocytic cells were transfected with each IL-32 iso-
form, or increasing amounts of pcDNA3.1+ 5ﬂag-IL-32d by using
a Neon™ transfection system (Invitrogen, Carlsbad, CA). The trans-
fected cells were incubated overnight, and 10 nM PMA was then
applied for 24 h, after which the culture medium was collected.Fig. 1. The effect of IL-32 isoforms on IL-10 production. IL-32 isoforms structures are sch
based on the literature of Goda et al. [4]. (A). U937 cells were electroporated with each
incubation after electroporation, cells were treated with 10 nM PMA for 24 h, then culture
myc antibody. The expression level of each isoform was conﬁrmed with 20 lg of whole c
n = 3; ⁄P < 0.05 for ev vs IL-32d (B).ELISAs for IL-10, IL-8, and TNF-a were performed using the respec-
tive commercial kits (R&D systems, Minneapolis, MN) according to
the manufacturer’s manuals. For co-localization analyses, A549
lung carcinoma cells were co-transfected with 1 lg of each
pcDNA3.1+ 6myc-IL-32b and pcDNA3.1+ 5ﬂag-PKCd, or 1 lg
of each plasmid plus 3 lg of pcDNA3.1+ IL-32d by using a Neon™
transfection system. After overnight incubation, cells were treated
with 5 lM of rottlerin for inhibitor-treated sample for 1 h, then
with 10 nM PMA for 1 h.
2.4. Immunoprecipitation and Western blotting
HEK293 cells were co-transfected with pcDNA3.1+ 6myc-IL-
32b and pcDNA3.1+ 5ﬂag-IL-32d, or pcDNA3.1+ 6myc-IL-32d
and pcDNA3.1+ 5ﬂag-IL-32b. To examine IL-32d effect, HEK293
cells were co-transfected with pcDNA3.1+ 6myc-IL-32b and
pcDNA3.1+ 5ﬂag-IL-32d, -PKCd. Cells were pre-treated for 1 h
with the PKCd inhibitor rottlerin (10 lM), and then treated with
PMA (20 nM) for 3 h. HEK293 cells were also co-transfeced with
pcDNA3.1+ 6myc-IL-32b, pcDNA3.1+ 5ﬂag-PKCd, and dose-
increasing pcDNA3.1+ 5  ﬂag-IL-32d. Overnight incubation after
transfection, cells were treated with 20 nM PMA for 3 h, then lysed
in 50 mM HEPES, pH 7.5, 150 mM NaCl, 5% glycerol, 20 mM
b-glycerophosphate, 0.5% NP-40, 0.1% TX-100, and 1 mM EDTA.
For immunoprecipitation, cell lysates were mixed with 1 lg of
myc antibody, 1 lg of ﬂag antibody, or 3 lg of PKCd antibody
and then pulled down using 35 ll of protein G agarose beadsematically illustrated. The exon numbers are shown upper the boxes. The schema is
of 3 lg of pcDNA3.1+ 6myc-IL-32a, b, c, d, f, e, or empty vector (ev). Overnight
media were collected for IL-10 ELISA, and cells were lysed for Western blotting with
ell lysates. GAPDH was used as a loading control. Values indicate the mean ± S.E.M.;
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myc tag antibody (Millipore-Upstate, Bedford, MA) and ﬂag anti-
body (Sigma).
2.5. Immunoﬂuorescence analyses
For co-localization analyses, A549 cells were grown on covelslip
after co-transfection with 6myc tagged-IL-32b and 5ﬂag
tagged-PKCd by electroporation. Cells were ﬁxed with 4% parafor-
maldehyde and permeabilized with 0.5% saponin for 5 min. After
blocking with 1% BSA, cells were incubated with primary antibod-
ies in 0.1% saponin. The antibodies were anti-myc (1:200) and anti-
ﬂag (1:200). After washing 3 times with PBS, cells were stained
with FITC-conjugated anti-mouse (1:400) and rhodamine-
conjugated anti-rabbit (1:400) in 0.1% saponine. DAPI was used
for nuclei staining. Fluorescence images were obtained by using
Olympus BX61-32FDIC upright ﬂuorescence microscope with
100 objective.
2.6. Statistical analysis
Statistical analysis was done by using the unpaired two-tailed
Student’s t-test. Differences were considered statistically
signiﬁcant at P < 0.05.Fig. 3. IL-32d interacts with IL-32b. HEK293 cells were co-transfected with
pcDNA3.1+ 6myc-IL-32b and pcDNA3.1+ 5ﬂag-IL-32d (A), or pcDNA3.1+
6myc-IL-32d and pcDNA3.1+ 5ﬂag-IL-32b (B). After overnight incubation,
immunoprecipitations were performed with 1 lg of ﬂag antibody, then Western
blotting were carried out with the both antibodies. The expression levels of the
transfected genes were conﬁrmed with 30 lg of whole cell lysates (WCL). Protein
size marker is indicated at right of each box.3. Results
3.1. IL-32d suppresses IL-10 production
Several isoforms of IL-32 are known to produce IL-10. We pre-
viously demonstrated that IL-32b upregulates IL-10 production inFig. 2. IL-32d inhibits IL-10 production in U937 cells. U937 cells were electroporated with
amount of the introduced DNA was adjusted to 3 lg with an empty vector. After overnigh
were then collected for ELISA for IL-10 (A), IL-8 (B), and TNF-a (C). Values indicate the ma PKCd-mediated way in myeloid cells. We investigated whether
there is any other IL-32 isoform to regulate IL-10 production, and
found that IL-32d decreased IL-10 production (Fig. 1B). The gene
structure of IL-32 isoforms in this study was schematically
depicted (Fig. 1A). We further conﬁrmed the inhibitory effect of
IL-32d on IL-10 production by transfection of IL-32d in a dose-
increasing way into U937 cells, which induced gradual decrease
of IL-10 production (Fig. 2A), but in contrast, IL-32d did not affect
the levels of TNF-a and IL-8 (Fig. 2B and C).
3.2. IL-32d interacts with IL-32b
The down-regulation of IL-10 production by IL-32d in U937 cells
is very interesting because U937 cells abundantly expressincreasing amounts of pcDNA3.1+ 5ﬂag-IL-32d (0, 0.1, 0.5, 1.5, and 3 lg). The total
t incubation, the cells were treated with 10 nM PMA for 24 h and the culture media
ean ± S.E.M.; n = 4; ⁄P < 0.03 for IL-32d 0.1 vs 0.5 lg, ⁄⁄P < 0.05 for IL-32d 0.5 vs 3 lg.
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promonocytic leukemia U937 cell line is useful for studying IL-32
function because it expresses the transcripts of IL-32b, IL-32c, IL-
32e, and IL-32g (data not shown). However, only IL-32b has been
characterized with regard to the upregulation of IL-10 in U937 cells
[16]. We previously showed that IL-32b associated with PKCd,
which induced IL-10 upregulation [23]. Hence, we examined
whether IL-32d has any effect on IL-32b function. We found that
IL-32d interacted with IL-32b (Fig. 3), which suggests that IL-32d
is involved in IL-32b function.
3.3. IL-32d inhibits the association of IL-32b with PKCd
We examined the interaction proﬁle between IL-32b, IL-32d,
and PKCd by using immunoprecipitation assays after cotransfec-
tion of HEK293 cells with the genes coding for these proteins. To
make the results clear, we transfected HEK293 cells because this
cell line does not express any endogenous IL-32 isoform (data
not shown). As shown in Fig. 4A, IL-32b associated with IL-32d
regardless of PMA treatment (lane 1). However, the interaction of
IL-32b with PKCd was PMA-dependent (lane 1 vs lane 2) as con-
ﬁrmed earlier [23]. Notably, when comparing lane 2 with lane 4,
IL-32d co-expression with IL-32b and PKCd resulted in the decrease
of the association between IL-32b and PKCd, which means that IL-
32d inhibited the interaction of IL-32b and PKCd. A PKCd-speciﬁc
inhibitor, rottlerin, did not inhibit the interaction of IL-32d with
IL-32b (lane 3). This result means that PKCd did not affect the inter-
action of IL-32d and IL-32b (lane 6). The same results were
obtained in an immunoprecipitation experiment with a PKCdFig. 4. The inhibitory effect of IL-32d on the interaction of IL-32b and PKCd. HEK293 cel
tagged IL-32d (A). After overnight incubation, a PKCd speciﬁc inhibitor rottlerin 5 lM wa
3 h. The immunoprecipitation assays were performed by using 1 lg of myc antibody (A) o
increasing amounts of IL-32d (0, 0.1, 0.5, and 1.5 lg). The total amount of DNA for trans
performed with 3 lg of the PKCd antibody (C) or 1 lg of the myc antibody (D). The exp
30 lg of whole cell lysates (WCL).antibody (Fig. 4B), where IL-32d suppressed the association of
IL-32b and PKCd (lane 2 vs lane 3). As consistent with Fig. 4A, IL-
32b interacted with PKCd upon PMA stimulation (lane 1 vs lane 2).
3.4. IL-32d negatively regulate IL-32b function through the dynamic
interaction with each other
To further verify that IL-32d is a negative regulator of IL-32b on
the IL-10 production, we next investigated the dynamics by
cotransfection with IL-32b, PKCd, and increasing amounts of IL-
32d. When PKCd was immunoprecipitated, the associated IL-32b
gradually decreased as the amount of transfected IL-32d increased.
In the immunoprecipitation of IL-32b, the pulled-down PKCd de-
creased, whereas the co-immunoprecipitated IL-32d increased
(Fig. 4C and D). These results conﬁrm that the association of IL-
32b with PKCd is suppressed by IL-32d.
We next veriﬁed the association proﬁle of IL-32d, IL-32b, and
PKCd by immunoﬂuorescence staining in A549 cells. Both IL-32b
and PKCd were distributed in the cytosol in normal condition.
However, they co-localized around the nucleus upon PMA treat-
ment. Rottlerin disrupted their co-localization. As consistent with
the immunoprecipitation data, IL-32d induced the dissociation of
IL-32b from PKCd (Fig. 5). These data conﬁrm the inhibitory effect
of IL-32d on IL-32b function.
4. Discussion
IL-32 is widely known as a proinﬂammatory cytokine whose
biological effects have been extensively studied. It is implicatedls were cotransfected with 6myc-tagged IL-32b, 5ﬂag-tagged PKCd, and 5ﬂag-
s treated for 1 h for inhibitor-treated samples, and then 20 nM PMA was treated for
r 3 lg of PKCd antibody (B). HEK293 cells were co-transfected with IL-32b, PKCd, and
fection was adjusted to 1.5 lg by using an empty vector. Immunoprecipitation was
ression levels of the transfected genes were determined by Western blottings with
Fig. 5. IL-32d disrupts the association of IL-32b and PKCd. A549 lung carcinoma cells were electroporated with 1 lg of the expression plasmids for pcDNA3.1+ 6myc-IL-32b,
pcDNA3.1+ 5ﬂag-PKCd, and 3 lg of pcDNA3.1+ IL-32d. After overnight incubation, cells were treated with 20 nM of PMA for 3 h. Rottlerin (5 lM) was treated 1 h before PMA
treatment. Immunoﬂuorescence signals were detected for PKCd (red), IL-32b (green), and the combined (yellow) by using upright ﬂuorescence microscope.
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ulcerative colitis, Crohn’s disease [13,26], and psoriasis [2,27,8]
as well as obstructive pulmonary disease [27], viral infections, bac-
terial infection, and cancer [29,30]. IL-32a and IL-32b have been
studied for their proinﬂammatory effects. IL-32b is known to in-
volve in activation-induced cell death in T cells [4]. IL-32c is re-
ported to be the most active isoform [31] and that induces the
differentiation of blood monocytes into macrophage-like cells
[20] and CD14+ monocytes into osteoclasts [18], as well as the
maturation and activation of dendritic cell [32]. However, IL-32c
tends to be spliced into shorter isoforms when ectopically ex-
pressed in cells. Splice-resistant IL-32cmutant shows much higher
induction of proinﬂammatory cytokines than IL-32b [15]. IL-32b
and IL-32c are also known for their effect on IL-10 induction
[16,33]. However, such pleiotropic effects have only been reported
for several isoforms thus far, even though more than 9 isoforms are
found in the GenBank Database.
Recently, IL-32 has been reported to interact with the extracel-
lular domain of integrins and intracellular proteins such as paxillin
and focal adhesion kinase-1 (FAK1) through its alpha helix region.
IL-32b is the most abundantly and broadly expressed isoform and
is known to promote IL-10 production in U937 cells upon PMA
stimulation as well as in the puriﬁed monocyte-derived dendritic
cells by LPS stimulation [16].
Many proteins have their alternatively spliced variants. The
existence of multiple isoforms of a protein owing to alternative
splicing may provide it functional relatedness. However, it is less
common that alternatively spliced isoforms of a protein interact
with each other to regulate its own function. One such a case is a
putative tumor suppressor protein Fbw 7, which is a speciﬁcityfactor for the Skp 1-Cul 1-F-box protein ubiquitin ligase complex.
Fbw 7 has three alternative splice variants that are unique only
at their N-termini but are otherwise identical as with IL-32 protein.
Fbw 7 promotes cyclin E turnover efﬁciency through its isoform
interaction [34]. In this study, we investigated the effects of other
isoforms of IL-32 on IL-10 production. IL-32d transcript is ex-
pressed in T cells and NK cells [4,10], but its function remains to
be elucidated. We showed for the ﬁrst time that IL-32d interaction
with IL-32b suppressed the association of IL-32b with PMA-acti-
vated PKCd, resulting in the decrease of IL-10 production in U937
cells. The results in Fig. 4C and D suggest that IL-32d competitively
inhibit the binding of IL-32b to PMA-activated PKCd. Our data
imply that there may be more interacting pairs between IL-32
isoforms and there may be more functional relationship between
IL-32 isoforms.
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